Back to Search
GERARDO CAMEJO, M.D.
M.D.
Internal Medicine Physician
NPI: 1851696728Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
124028(NY)
Research & Publications (20)
Hypoxia increases macrophage motility, possibly by decreasing the heparan sulfate proteoglycan biosynthesis.
PMID 19401393·J Leukoc Biol·2009
8-other
The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
PMID 19220285·Br J Pharmacol·2009
7-preclinical
In vivo effects of myocardial creatine depletion on left ventricular function morphology and lipid metabolism: study in a mouse model.
PMID 18325464·J Card Fail·2008
7-preclinical
Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr.
PMID 18025001·J Lipid Res·2008
4-observational
Fatty acid-induced atherogenic changes in extracellular matrix proteoglycans.
PMID 17885426·Curr Opin Lipidol·2007
6-review
Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.
PMID 17468185·Toxicol Sci·2007
7-preclinical
Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat.
PMID 17164430·Am J Physiol Endocrinol Metab·2007
7-preclinical
Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis.
PMID 17070102·Biochim Biophys Acta·2006
6-review
Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
PMID 16931788·Arterioscler Thromb Vasc Biol·2006
7-preclinical
Fatty acids cause alterations of human arterial smooth muscle cell proteoglycans that increase the affinity for low-density lipoprotein.
PMID 16239593·Arterioscler Thromb Vasc Biol·2006
8-other
Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.
PMID 16183630·Am J Physiol Regul Integr Comp Physiol·2005
7-preclinical
Differential antiatherogenic effects of PPARalpha versus PPARgamma agonists: should we be surprised?
PMID 16127025·Arterioscler Thromb Vasc Biol·2005
7-preclinical
A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes.
PMID 15995172·J Lipid Res·2005
7-preclinical
Hydrolytic enzymes released from resident macrophages and located in the intima extracellular matrix as agents that modify retained apolipoprotein B lipoproteins.
PMID 12909567·Arterioscler Thromb Vasc Biol·2003
8-other
Fatty acids modulate the effect of darglitazone on macrophage CD36 expression.
PMID 12795642·Eur J Clin Invest·2003
8-other
PPAR agonists in the treatment of insulin resistance and associated arterial disease.
PMID 12793596·Int J Clin Pract Suppl·2003
6-review
Phospholipase A2 modification of lipoproteins: potential effects on atherogenesis.
PMID 12664556·Adv Exp Med Biol·2002
6-review
AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.
PMID 12401884·J Lipid Res·2002
7-preclinical
Correction of dysfunctional fatty acid metabolism using peroxisome proliferator activated receptor gamma agonists.
PMID 12216325·J R Soc Med·2002
6-review
The extracellular matrix on atherogenesis and diabetes-associated vascular disease.
PMID 12044579·Atheroscler Suppl·2002
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 150 W END AVE APT 17K
NEW YORK, NY 10023 - Phone
- (646) 797-3483
Quick Facts
- NPI
- 1851696728
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile